Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: A comparative study on the efficacies of gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist in neoadjuvant androgen deprivation therapy combined with transperineal prostate brachytherapy for localized prostate cancer

Fig. 1

Study design (UMIN000015519). Patients who meet the inclusion criteria are enrolled and randomized. Patients receive 12 weeks’ neoadjuvant therapy with GnRH agonists or degarelix followed by 48 weeks of follow-up after 125I-TPPB. Arrowheads show the time points for assessments

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us